Want to create an interactive transcript for this episode?
Podcast: Money Matters with Hongbin Jeong and Chua Tian Tian
Episode: Under the Radar: How is Wegovy and Ozempic maker Novo Nordisk navigating the next battleground for anti-obesity medication with its GLP-1 oral pills, and how far is it diversifying beyond metabolic health to manage long-term risks?
Description: Today we’re going to take you through the company behind the GLP-1 drugs Wegovy and Ozempic that are used to treat obesity and diabetes. Founded in 1923 and headquartered just outside Copenhagen in Denmark, Novo Nordisk prides itself as a global healthcare company that aims to drive change to defeat serious chronic disease and build on its heritage in diabetes. The Danish drugmaker said it seeks to do so by pioneering scientific breakthroughs, expanding access to its medicines and working to prevent and ultimately cure the diseases it treats. Fast forward to today, Novo...